TRADING UPDATES: Microsaic completes acquisition; Narf revenue soars
25th Jan 2024 20:09
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday announced that the first patient has been dosed in phase 2 of its Bexmab trial. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said results from a probe of a cancer drug were promising. Read More
Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Says that results from its Phase 1/2 MATINS trial of bexmarilimab have been published in Cell Reports Medicine, an open-access journal. According to the trial, bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumours. It also showed that CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects, and that bexmarilimab induced macrophage activation and increased IFNy signalling in patients who achieved disease control and prolonged survival. Read More
Faron Pharmaceuticals Ltd - Finland-based clinical-stage biopharmaceutical company - Initiates Phase 2 of Bexmab study investigating humanised antibody bexmarilimab in patients with aggressive myeloid leukemias. Says it has selected hypomethylating agents-refractory or relapsed myelodysplastic syndromes (MDS) as the initial indication, based on US Food & Drug Administration guidance. Phase 1 data "demonstrated that optimal target engagement can be achieved with three milligrams per kilogram dosing" with both three and six milligram cohorts showing the "highest immune activation", while the drug produced a 50% remission rate in doublet dose cohorts. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Says Bexmarilimab study shows 50% remission rate for patients with in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Says eight of eleven patients were complete responders or complete responders with incomplete blood recovery. Adds Bexmarilimab continues to be well-tolerated at all tested dose levels, as no dose-limiting toxicity has been observed. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its interim loss widened on higher costs but saw shares soar after it gained a US Food & Drug Administration orphan drug designation for Bexmarilimab. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said data from its phase 1 BEXMAB study has shown positive data. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Friday and not separately reported by Alliance News: Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said further data from its Phase I/II MATINS study of bexmarilimab has indicated the efficacy and safety of the immunotherapy in solid tumours. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said it has appointed James O'Brien as its new chief financial officer, effective from Monday next week, succeeding Toni Hanninen. Read More